Clinical impact of oral antidiabetic medications in heart failure patients

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Heart failure (HF) is a significant complication in type 2 diabetes, linked to high morbidity and mortality.
• Elevated HbA1c levels correlate with cardiovascular events, but glycemic control's impact on HF incidence remains debated.
• New antidiabetic drugs offer potential benefits, yet their precise effects on HF are under investigation.

Purpose of the Study:

• To review the specific effects of various antidiabetic drug classes on heart failure in type 2 diabetes patients.
• To elucidate the clinical impact of antidiabetic medications on HF occurrence and progression.
• To guide clinicians in selecting optimal, individualized therapies for diabetic patients with HF.

Main Methods:

• Review of current literature on antidiabetic medications and their cardiovascular effects.
• Analysis of metabolic and biomolecular signaling pathways influenced by different drug classes.
• Examination of clinical trial data and observational studies regarding HF incidence and outcomes.

Main Results:

• Thiazolidinediones may negatively impact HF prognosis and cardiac function.
• GLP-1 receptor agonists demonstrate cardioprotective effects by reducing apoptosis and oxidative stress.
• DPP-4 inhibitors show mixed results, with some increasing HF risk (saxagliptin, alogliptin) and others not (vildagliptin, sitagliptin).
• Metformin's activation of 5-AMPK may contribute to reduced HF events.
• SGLT2 inhibitors, particularly empagliflozin, show a significant reduction (38%) in HF incidence and mortality.

Conclusions:

• Antidiabetic drug classes exhibit distinct effects on heart failure in type 2 diabetes.
• SGLT2 inhibitors represent a promising therapeutic option for reducing HF risk in this population.
• Individualized treatment strategies considering the specific drug class effects are crucial for managing diabetic patients with HF.